Cross-Platform Comparison of Highly Sensitive Immunoassays for Inflammatory Markers in a COVID-19 Cohort
Copyright © 2024 by The American Association of Immunologists, Inc..
A variety of commercial platforms are available for the simultaneous detection of multiple cytokines and associated proteins, often employing Ab pairs to capture and detect target proteins. In this study, we comprehensively evaluated the performance of three distinct platforms: the fluorescent bead-based Luminex assay, the proximity extension-based Olink assay, and a novel proximity ligation assay platform known as Alamar NULISAseq. These assessments were conducted on human serum samples from the National Institutes of Health IMPACC study, with a focus on three essential performance metrics: detectability, correlation, and differential expression. Our results reveal several key findings. First, the Alamar platform demonstrated the highest overall detectability, followed by Olink and then Luminex. Second, the correlation of protein measurements between the Alamar and Olink platforms tended to be stronger than the correlation of either of these platforms with Luminex. Third, we observed that detectability differences across the platforms often translated to differences in differential expression findings, although high detectability did not guarantee the ability to identify meaningful biological differences. Our study provides valuable insights into the comparative performance of these assays, enhancing our understanding of their strengths and limitations when assessing complex biological samples, as exemplified by the sera from this COVID-19 cohort.
| Errataetall: | |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:212 |
|---|---|
| Enthalten in: |
Journal of immunology (Baltimore, Md. : 1950) - 212(2024), 7 vom: 01. März, Seite 1244-1253 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Abe, Koji [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 20.03.2024 Date Revised 20.03.2024 published: Print UpdateOf: bioRxiv. 2023 Oct 26;:. - PMID 37961126 Citation Status MEDLINE |
|---|
| doi: |
10.4049/jimmunol.2300729 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM368239446 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM368239446 | ||
| 003 | DE-627 | ||
| 005 | 20240320234147.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240209s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.4049/jimmunol.2300729 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1337.xml |
| 035 | |a (DE-627)NLM368239446 | ||
| 035 | |a (NLM)38334457 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Abe, Koji |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Cross-Platform Comparison of Highly Sensitive Immunoassays for Inflammatory Markers in a COVID-19 Cohort |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 20.03.2024 | ||
| 500 | |a Date Revised 20.03.2024 | ||
| 500 | |a published: Print | ||
| 500 | |a UpdateOf: bioRxiv. 2023 Oct 26;:. - PMID 37961126 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2024 by The American Association of Immunologists, Inc. | ||
| 520 | |a A variety of commercial platforms are available for the simultaneous detection of multiple cytokines and associated proteins, often employing Ab pairs to capture and detect target proteins. In this study, we comprehensively evaluated the performance of three distinct platforms: the fluorescent bead-based Luminex assay, the proximity extension-based Olink assay, and a novel proximity ligation assay platform known as Alamar NULISAseq. These assessments were conducted on human serum samples from the National Institutes of Health IMPACC study, with a focus on three essential performance metrics: detectability, correlation, and differential expression. Our results reveal several key findings. First, the Alamar platform demonstrated the highest overall detectability, followed by Olink and then Luminex. Second, the correlation of protein measurements between the Alamar and Olink platforms tended to be stronger than the correlation of either of these platforms with Luminex. Third, we observed that detectability differences across the platforms often translated to differences in differential expression findings, although high detectability did not guarantee the ability to identify meaningful biological differences. Our study provides valuable insights into the comparative performance of these assays, enhancing our understanding of their strengths and limitations when assessing complex biological samples, as exemplified by the sera from this COVID-19 cohort | ||
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Cytokines |2 NLM | |
| 700 | 1 | |a Beer, Joanne C |e verfasserin |4 aut | |
| 700 | 1 | |a Nguyen, Tran |e verfasserin |4 aut | |
| 700 | 1 | |a Ariyapala, Ishara S |e verfasserin |4 aut | |
| 700 | 1 | |a Holmes, Tyson H |e verfasserin |4 aut | |
| 700 | 1 | |a Feng, Wei |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Bingqing |e verfasserin |4 aut | |
| 700 | 1 | |a Kuo, Dwight |e verfasserin |4 aut | |
| 700 | 1 | |a Luo, Yuling |e verfasserin |4 aut | |
| 700 | 1 | |a Ma, Xiao-Jun |e verfasserin |4 aut | |
| 700 | 1 | |a Maecker, Holden T |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of immunology (Baltimore, Md. : 1950) |d 1945 |g 212(2024), 7 vom: 01. März, Seite 1244-1253 |w (DE-627)NLM000018554 |x 1550-6606 |7 nnns |
| 773 | 1 | 8 | |g volume:212 |g year:2024 |g number:7 |g day:01 |g month:03 |g pages:1244-1253 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.4049/jimmunol.2300729 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 212 |j 2024 |e 7 |b 01 |c 03 |h 1244-1253 | ||